目的 探讨多重耐药肺炎克雷伯杆菌(MDR-KP)脓毒症感染的危险因素,为防止和减少MDRKP脓毒症的发生以及合理使用抗生素提供参考依据。方法 采用回顾性病例对照研究方法,选取2010 年3 月至2014 年2 月41 例MDR-KP 脓毒症患儿作为病例组,选择同期53 例非MDR-KP 脓毒症患儿作为对照组。采用多元logistic 回归分析对肺炎克雷伯杆菌脓毒症感染的独立危险因素进行评价。结果 病例组感染前PICU 住院天数、感染前机械通气天数、机械通气总天数及感染前抗生素使用天数均明显长于对照组(P<0.05),感染前抗生素使用种类及病死率均明显高于对照组(P<0.05)。Logistic 回归分析结果显示感染前抗生素使用种类及使用三代头孢、碳青霉烯类抗生素是MDR-KP感染的独立危险因素(P<0.05)。结论 合理使用抗生素是防止MDR-KP感染发生的有效措施。
Abstract
Objective To explore the risk factors for sepsis caused by multidrug-resistant Klebsiella pneumonia (MDR-KP) and to provide a reference for the prevention of MDR-KP sepsis and rational use of antibiotics.Methods A retrospective case-control study of 41 children with MDR-KP sepsis (case group) and 53 pediatric patients without MDR-KP sepsis (control group) between March 2010 and Febrary 2014 was conducted. Multiple logistic regression analysis was performed to estimate the independent risk factors for MDR-KP sepsis.Results Compared with the control group, the case group had a longer length of stay in the PICU before infection (P<0.05), more prolonged duraion of mechanical ventilation before infection (P<0.05), a larger total number of days of mechanical ventilation (P<0.05), more days of antibiotic use before infection (P<0.05), more types of antibiotics used before infection (P<0.05), and a higher mortality (P<0.05). The logistic regression analysis showed that more types of antibiotics used before infection and use of third-generation cephalosporin and carbapenems were independent risk factors for MDR-KP sepsis (P<0.05).Conclusions Rational use of antibiotics is an effective measure to prevent MDR-KP sepsis.
关键词
多重耐药肺炎克雷伯杆菌 /
脓毒症 /
危险因素 /
儿童
Key words
Multidrug resistant Klebsiella Pneumoniae /
Sepsis /
Risk factor /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 邱令法, 裴碧娜. 产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的检测和耐药性分析[J]. 检验医学, 2012, 27(5):421-423.
[2] Dass R, Deak NM, Barman H, et al. Empyema thoracis:analysis of 150 cases from a teriatry care centre in North East India[J]. Indian J Pediatr, 2011, 78(11):1371.
[3] 陆国健. 细菌性肺炎患儿肺炎克雷伯菌的检出率及其耐药性[J]. 中国医药指南, 2013, 11(13):657-658.
[4] Chen LF, Anderson DJ, Paterson DL. Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance[J]. Infect Drug Resist, 2012, 5:133-141.
[5] Saidel-Odes L, Borer A. Limiting and controlling carbapenemresistant Klebsiella pneumoniae[J]. Infect Drug Resist, 2014, 7:9-14.
[6] Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City:a new threat to our antibiotic armamentarium[J]. Arch Intern Med, 2005, 165(12):1430-1435.
[7] Woodford N, Tierno PM, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A betalactamase, KPC-3, in a New York Medical Center[J]. Antimicrob Agents Chemother, 2004, 48(12):4793-4799.
[8] Chia JH, Su LH, Lee MH, et al. Development of high-level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure[J]. Microb Drug Resist, 2010, 16(4):317-325.
[9] 贺湘玲, 张先华, 张兵, 等. 小儿肺炎克雷伯杆菌感染危险 因素的logistic 回归分析[J]. 医学临床研究, 2003, 20(12):892-894.
[10] 樊寻梅, 武志远. 国际儿科脓毒症定义会议介绍[J]. 中华儿科杂志, 2005, 42(8):618-620.
[11] 许景峰, 徐琳, 樊卫红. 肺炎克雷伯菌对抗生素的耐药性研 究[J]. 中华现代临床医学杂志, 2007, 5(1):4-7.
[12] Bouza E, Cercenado E. Klebsiella and enterobacter antibiotic resistance and treatment implications[J]. Semin Res Pir Infect, 2002, 17(3):215-230.
[13] 章惠彬, 应益人, 童其田. 婴儿下呼吸道感染的肺炎克雷伯菌耐药性分析[J]. 上海预防医学杂志, 2009, 21(12):599-600.
[14] Borer A, Saidel-Odes L, Eskira S, et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae[J]. Am J Infect Control, 2012, 40(5):421-425.
[15] Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae[J]. South Med J, 2011, 104(2):106-110.
[16] Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospitalacquired bacteraemia caused by Klebsiella pneumoniae[J]. Hosp Infect, 2013, 83(4):307-313.
[17] Chia JH, Su LH, Lee MH, et al. Development of high-level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure[J]. Microb Drug Resist, 2010, 16(4):317-325.
[18] Schechner V, Kotlovsky T, Kazma M, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae:who is prone to become clinically infected[J]. Clin Microbiol Infect, 2013, 19(5):451-456.
[19] Borer A, Eskira S, Nativ R, et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel[J]. Infect Control Hosp Epidemiol, 2011, 32(12):1158-1165.
[20] Ciobotaro P, Oved M, Nadir E, et al. An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting:from theory to practice[J]. Am J Infect Control, 2011, 39(8):671-677.
[21] Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae at a long-term acute care hospital[J]. Infect Control Hosp Epidemiol, 2010, 31(4):341-347.
[22] Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae[J]. Infect Control Hosp Epidemiol, 2009, 30(5):447-452.
PDF(1274 KB)
